North America Point Of Care (PoC) Diagnostics Market Analysis By Product (Glucose Testing, Hb1ac Testing, Coagulation, Fertility, Cardiac Markers, Infectious Diseases, Primary Acre Systems, Hematology, Decentralized Clinical Chemistry, Feces, Blood Gas Electrolytes, Ambulatory Chemistry, Urinalysis, Drug Abuse Testing, HIV, Clostridium Difficile, HBV, Pneumonia Or Streptococcus Associated Infections, Respiratory Syncytial Virus (RSV)) By End-Use And Segment Forecasts To 2024
The North America point of care diagnostics market is anticipated to reach USD 8.95 billion by 2024, according to a new report by Grand View Research, Inc. Incorporation of advanced information technology solutions coupled with the launch of innovative POC products with automation and ease of use is projected to influence market progression during the forecast period.
Moreover, the rising adoption rate of the POC devices in order to obtain quick results for immediate decision making for patient management is expected to provide the market with lucrative growth avenues.Additionally, the regulatory initiatives introduced for patient care management and rising prevalence of various diseases is attributive to boost demand for these products in the coming years.
The presence of a favorable funding environment in the region is attributive to drive R&D in academic organizations and universities thereby resulting to industrial progress through to 2024.
Further key findings from the report suggest:
Glucose testing accounted for the largest share of over 41% of the market in 2015 with respect to revenue generation. Factors attributive for the estimated large share includes presence of comprehensive product portfolio provided by the local as well as international market participants. Moreover, rise in the prevalence of diabetes in chronic patients and need for monitoring glucose levels is also supportive for revenue generation of this segment.
Infectious diseases point-of-care tests are expected to witness the fastest growth in the coming years owing to the R&D carried out in this segment for an introduction of novel tests. Infectious disease testing segments include kits for various diseases such as HIV, HBV, respiratory syncytial virus (RSV), pneumonia or streptococcus associated infections, HPV, influenza/flu, HCV, MRSA, Clostridium difficile, TB &drug-resistant TB, and HSV.
Cardiac markers are also anticipated to register substantial growth as a result of an increase in incidence rate of cholesterol associated disorders and rise in the number of cases of congestive heart failure.
Clinics dominated the POC diagnostic market in 2015 due to higher usage of these tests in clinics. However, home settings for POC diagnostics are anticipated to witness the fastest growth owing to rising usage of home health care settings for disease monitoring in the geriatric population.
Assisted living healthcare facilities are also anticipated to witness considerable growth during the forecast period due to the property of rapid diagnostic products to enable simple usage at primary care level and in remote settings even with no laboratory infrastructure
Prominent players of this industry include Qiagen N.V., Spectral Diagnostics, Abbott Laboratories, Siemens Healthcare, Instrumentation Laboratory, Danaher Corporation, BioMerieux, Johnson & Johnson, Abaxis Inc., Roche Diagnostics, Alere Inc., Nova Biomedical, Nipro Diagnostics, and Trinity Biotech.
Strategies adopted by the market players include mergers and acquisitions with the smaller entities operating in market for enhancement of the product portfolio. The participants are involved introduction of new solutions, and collaborations with heath care institutions in order to maintain their global presence.
Moreover, the rising adoption rate of the POC devices in order to obtain quick results for immediate decision making for patient management is expected to provide the market with lucrative growth avenues.Additionally, the regulatory initiatives introduced for patient care management and rising prevalence of various diseases is attributive to boost demand for these products in the coming years.
The presence of a favorable funding environment in the region is attributive to drive R&D in academic organizations and universities thereby resulting to industrial progress through to 2024.
Further key findings from the report suggest:
Glucose testing accounted for the largest share of over 41% of the market in 2015 with respect to revenue generation. Factors attributive for the estimated large share includes presence of comprehensive product portfolio provided by the local as well as international market participants. Moreover, rise in the prevalence of diabetes in chronic patients and need for monitoring glucose levels is also supportive for revenue generation of this segment.
Infectious diseases point-of-care tests are expected to witness the fastest growth in the coming years owing to the R&D carried out in this segment for an introduction of novel tests. Infectious disease testing segments include kits for various diseases such as HIV, HBV, respiratory syncytial virus (RSV), pneumonia or streptococcus associated infections, HPV, influenza/flu, HCV, MRSA, Clostridium difficile, TB &drug-resistant TB, and HSV.
Cardiac markers are also anticipated to register substantial growth as a result of an increase in incidence rate of cholesterol associated disorders and rise in the number of cases of congestive heart failure.
Clinics dominated the POC diagnostic market in 2015 due to higher usage of these tests in clinics. However, home settings for POC diagnostics are anticipated to witness the fastest growth owing to rising usage of home health care settings for disease monitoring in the geriatric population.
Assisted living healthcare facilities are also anticipated to witness considerable growth during the forecast period due to the property of rapid diagnostic products to enable simple usage at primary care level and in remote settings even with no laboratory infrastructure
Prominent players of this industry include Qiagen N.V., Spectral Diagnostics, Abbott Laboratories, Siemens Healthcare, Instrumentation Laboratory, Danaher Corporation, BioMerieux, Johnson & Johnson, Abaxis Inc., Roche Diagnostics, Alere Inc., Nova Biomedical, Nipro Diagnostics, and Trinity Biotech.
Strategies adopted by the market players include mergers and acquisitions with the smaller entities operating in market for enhancement of the product portfolio. The participants are involved introduction of new solutions, and collaborations with heath care institutions in order to maintain their global presence.
CHAPTER 1 RESEARCH METHODOLOGY & SCOPE
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET SNAPSHOT
CHAPTER 4 MARKET VARIABLES, TRENDS& SCOPE
4.1 Market segmentation& scope
4.1.1 Market Driver Analysis
4.1.1.1 Rise in incidence rate of chronic and infectious diseases
4.1.1.2 Improved turnaround time for medical decision-making
4.1.1.3 High usage preference of home or near-patient testing based innovative POC devices
4.1.1.4 Rise in funding from government and private institutions
4.1.1.5 Decrease in the number of skilled technicians
4.1.2 Market Restraint Analysis
4.1.2.1 Stringent regulatory framework
4.2 Penetration & growth prospect mapping
4.3 Point of care diagnostics - SWOT Analysis, By Factor (political & legal, economic and technological)
4.4 Industry Analysis - Porter’s
4.5 Product ppsitioning Analysis
CHAPTER 5 MARKET CATEGORIZATION 1: PRODUCT ESTIMATES & TREND ANALYSIS
5.1 Point of care diagnostics market: Product movement analysis
5.2 Glucose testing
5.2.1 North AmericaGlucose testing market, 2013 - 2024 (USD Million)
5.3 Hb1Ac Testing
5.3.1 North America Hb1Ac testing market, 2013 - 2024 (USD Million)
5.4 Coagulation testing
5.4.1 North America Coagulation testing market, 2013 - 2024 (USD Million)
5.5 Fertility testing
5.5.1 North America Fertilty testing market, 2013 - 2024 (USD Million)
5.6 Cardiac markers
5.6.1 North America Cardiac markers market, 2013 - 2024 (USD Million)
5.7 Infectious disaese testing
5.7.1 North America Infectious disease testing market, 2013 - 2024 (USD Million)
5.7.2 HIV POC
5.7.2.1 HIV POC market, 2013 - 2024 (USD Million)
5.7.3 Clostridium difficile POC
5.7.3.1 Clostridium difficile POC market, 2013 - 2024 (USD Million)
5.7.4 HBV POC
5.7.4.1 HBV POC market, 2013 - 2024 (USD Million)
5.7.5 Pneumonia or Streptococcus associated infections
5.7.5.1 Pneumonia or Streptococcus associated infections market, 2013 - 2024 (USD Million)
5.7.6 Respiratory syncytial virus (RSV) POC
5.7.6.1 Respiratory syncytial virus (RSV) POC market, 2013 - 2024 (USD Million)
5.7.7 HPV POC
5.7.7.1 HPV POC market, 2013 - 2024 (USD Million)
5.7.8 Influenza/Flu POC
5.7.8.1 Influenza/Flu POC market, 2013 - 2024 (USD Million)
5.7.9 HCV POC
5.7.9.1 HCV POC market, 2013 - 2024 (USD Million)
5.7.10 MRSA POC
5.7.10.1 MRSA POC market, 2013 - 2024 (USD Million)
5.7.11 TB and drug-resistant TB POC
5.7.11.1 TB and drug-resistant TB POC market, 2013 - 2024 (USD Million)
5.7.12 HSV POC
5.7.12.1 HSV POC market, 2013 - 2024 (USD Million)
5.7.13 Other Infectious Diseases
5.7.13.1 Other Infectious Diseases market, 2013 - 2024 (USD Million)
5.8 Primary care systems
5.8.1 North America Primary care systemsmarket, 2013 - 2024 (USD Million)
5.9 Heamatology testing
5.9.1 North America Hematology testing market, 2013 - 2024 (USD Million)
5.10 Decentralized clinical chemistry
5.10.1 North America Decentralized clinical chemistry market, 2013 - 2024 (USD Million)
5.11 Blood gas/electrolytes testing
5.11.1 North America Blood gas/electrolytes testing market, 2013 - 2024 (USD Million)
5.12 Ambulatory chemistry
5.12.1 North America Ambulatory chemistry market, 2013 - 2024 (USD Million)
5.13 Urinanalysis
5.13.1 North America Urinanalysis market, 2013 - 2024 (USD Million)
5.14 Drug abuse testing
5.14.1 North America Drug abuse testing market, 2013 - 2024 (USD Million)
CHAPTER 6 MARKET CATEGORIZATION 2: END-USE ESTIMATES & TREND ANALYSIS
6.1 Point of care diagnostics market:end-use movement analysis
6.2 Clinics
6.2.1 North America Clinics market, 2013 - 2024 (USD Million)
6.3 Hospitals
6.3.1 North America Hospitals market, 2013 - 2024 (USD Million)
6.4 Home
6.4.1 North America Home market, 2013 - 2024 (USD Million)
6.5 Assiated living healthcare facilities
6.5.1 North America Assiated living healthcare facilities market, 2013 - 2024 (USD Million)
6.6 Laboratories
6.6.1 North America Laboratories market, 2013 - 2024 (USD Million)
6.7 Others
6.7.1 North America Other end-use market, 2013 - 2024 (USD Million)
CHAPTER 7 MARKET CATEGORIZATION 3: REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT, & END-USE
7.1 Point of care diagnostics market share by region, 2015 & 2024
7.2 North America
7.2.1 North America point of care diagnostics market, 2013 - 2024 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. point of care diagnostics market, 2013 - 2024 (USD Million)
7.2.3 Canada.
7.2.3.1 Canada point of care diagnostics market, 2013 - 2024 (USD Million)
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 Strategy framework
8.2 Market participation categorization
8.3 Company Profiles
8.3.1 Roche Diagnostics
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 Abbott Diagnostics Inc
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Siemens Healthcare
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Danaher Corporation (Beckman Coulter Inc. and Radiometer)
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 bioMerieux
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Abaxis, Inc.
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Alere, Inc.
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 Qiagen N.V.
8.3.8.1 Company Overview
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 Spectral Diagnostics
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 Instrumentation Laboratory
8.3.10.1 Company Overview
8.3.10.2 Financial Performance
8.3.10.3 Product Benchmarking
8.3.10.4 Strategic Initiatives
8.3.11 Johnson and Johnson
8.3.11.1 Company Overview
8.3.11.2 Financial Performance
8.3.11.3 Product Benchmarking
8.3.11.4 Strategic Initiatives
8.3.12 Nova Biomedical
8.3.12.1 Company Overview
8.3.12.2 Financial Performance
8.3.12.3 Product Benchmarking
8.3.12.4 Strategic Initiatives
8.3.13 Nipro Diagnostics Inc
8.3.13.1 Company Overview
8.3.13.2 Financial Performance
8.3.13.3 Product Benchmarking
8.3.13.4 Strategic Initiatives
8.3.14 HemoCue AB
8.3.14.1 Company Overview
8.3.14.2 Financial Performance
8.3.14.3 Product Benchmarking
8.3.14.4 Strategic Initiatives
8.3.15 International Technidyne Corporation (ITC)
8.3.15.1 Company Overview
8.3.15.2 Financial Performance
8.3.15.3 Product Benchmarking
8.3.15.4 Strategic Initiatives
8.3.16 Quidel Corporation
8.3.16.1 Company Overview
8.3.16.2 Financial Performance
8.3.16.3 Product Benchmarking
8.3.16.4 Strategic Initiatives
8.3.17 Trinity Biotech PLC
8.3.17.1 Company Overview
8.3.17.2 Financial Performance
8.3.17.3 Product Benchmarking
8.3.17.4 Strategic Initiatives
8.3.18 Sekisui Diagnostics LLC
8.3.18.1 Company Overview
8.3.18.2 Financial Performance
8.3.18.3 Product Benchmarking
8.3.18.4 Strategic Initiatives
8.3.19 OraSure Technologies Inc
8.3.19.1 Company Overview
8.3.19.2 Financial Performance
8.3.19.3 Product Benchmarking
8.3.19.4 Strategic Initiatives
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET SNAPSHOT
CHAPTER 4 MARKET VARIABLES, TRENDS& SCOPE
4.1 Market segmentation& scope
4.1.1 Market Driver Analysis
4.1.1.1 Rise in incidence rate of chronic and infectious diseases
4.1.1.2 Improved turnaround time for medical decision-making
4.1.1.3 High usage preference of home or near-patient testing based innovative POC devices
4.1.1.4 Rise in funding from government and private institutions
4.1.1.5 Decrease in the number of skilled technicians
4.1.2 Market Restraint Analysis
4.1.2.1 Stringent regulatory framework
4.2 Penetration & growth prospect mapping
4.3 Point of care diagnostics - SWOT Analysis, By Factor (political & legal, economic and technological)
4.4 Industry Analysis - Porter’s
4.5 Product ppsitioning Analysis
CHAPTER 5 MARKET CATEGORIZATION 1: PRODUCT ESTIMATES & TREND ANALYSIS
5.1 Point of care diagnostics market: Product movement analysis
5.2 Glucose testing
5.2.1 North AmericaGlucose testing market, 2013 - 2024 (USD Million)
5.3 Hb1Ac Testing
5.3.1 North America Hb1Ac testing market, 2013 - 2024 (USD Million)
5.4 Coagulation testing
5.4.1 North America Coagulation testing market, 2013 - 2024 (USD Million)
5.5 Fertility testing
5.5.1 North America Fertilty testing market, 2013 - 2024 (USD Million)
5.6 Cardiac markers
5.6.1 North America Cardiac markers market, 2013 - 2024 (USD Million)
5.7 Infectious disaese testing
5.7.1 North America Infectious disease testing market, 2013 - 2024 (USD Million)
5.7.2 HIV POC
5.7.2.1 HIV POC market, 2013 - 2024 (USD Million)
5.7.3 Clostridium difficile POC
5.7.3.1 Clostridium difficile POC market, 2013 - 2024 (USD Million)
5.7.4 HBV POC
5.7.4.1 HBV POC market, 2013 - 2024 (USD Million)
5.7.5 Pneumonia or Streptococcus associated infections
5.7.5.1 Pneumonia or Streptococcus associated infections market, 2013 - 2024 (USD Million)
5.7.6 Respiratory syncytial virus (RSV) POC
5.7.6.1 Respiratory syncytial virus (RSV) POC market, 2013 - 2024 (USD Million)
5.7.7 HPV POC
5.7.7.1 HPV POC market, 2013 - 2024 (USD Million)
5.7.8 Influenza/Flu POC
5.7.8.1 Influenza/Flu POC market, 2013 - 2024 (USD Million)
5.7.9 HCV POC
5.7.9.1 HCV POC market, 2013 - 2024 (USD Million)
5.7.10 MRSA POC
5.7.10.1 MRSA POC market, 2013 - 2024 (USD Million)
5.7.11 TB and drug-resistant TB POC
5.7.11.1 TB and drug-resistant TB POC market, 2013 - 2024 (USD Million)
5.7.12 HSV POC
5.7.12.1 HSV POC market, 2013 - 2024 (USD Million)
5.7.13 Other Infectious Diseases
5.7.13.1 Other Infectious Diseases market, 2013 - 2024 (USD Million)
5.8 Primary care systems
5.8.1 North America Primary care systemsmarket, 2013 - 2024 (USD Million)
5.9 Heamatology testing
5.9.1 North America Hematology testing market, 2013 - 2024 (USD Million)
5.10 Decentralized clinical chemistry
5.10.1 North America Decentralized clinical chemistry market, 2013 - 2024 (USD Million)
5.11 Blood gas/electrolytes testing
5.11.1 North America Blood gas/electrolytes testing market, 2013 - 2024 (USD Million)
5.12 Ambulatory chemistry
5.12.1 North America Ambulatory chemistry market, 2013 - 2024 (USD Million)
5.13 Urinanalysis
5.13.1 North America Urinanalysis market, 2013 - 2024 (USD Million)
5.14 Drug abuse testing
5.14.1 North America Drug abuse testing market, 2013 - 2024 (USD Million)
CHAPTER 6 MARKET CATEGORIZATION 2: END-USE ESTIMATES & TREND ANALYSIS
6.1 Point of care diagnostics market:end-use movement analysis
6.2 Clinics
6.2.1 North America Clinics market, 2013 - 2024 (USD Million)
6.3 Hospitals
6.3.1 North America Hospitals market, 2013 - 2024 (USD Million)
6.4 Home
6.4.1 North America Home market, 2013 - 2024 (USD Million)
6.5 Assiated living healthcare facilities
6.5.1 North America Assiated living healthcare facilities market, 2013 - 2024 (USD Million)
6.6 Laboratories
6.6.1 North America Laboratories market, 2013 - 2024 (USD Million)
6.7 Others
6.7.1 North America Other end-use market, 2013 - 2024 (USD Million)
CHAPTER 7 MARKET CATEGORIZATION 3: REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT, & END-USE
7.1 Point of care diagnostics market share by region, 2015 & 2024
7.2 North America
7.2.1 North America point of care diagnostics market, 2013 - 2024 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. point of care diagnostics market, 2013 - 2024 (USD Million)
7.2.3 Canada.
7.2.3.1 Canada point of care diagnostics market, 2013 - 2024 (USD Million)
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 Strategy framework
8.2 Market participation categorization
8.3 Company Profiles
8.3.1 Roche Diagnostics
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 Abbott Diagnostics Inc
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Siemens Healthcare
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Danaher Corporation (Beckman Coulter Inc. and Radiometer)
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 bioMerieux
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Abaxis, Inc.
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Alere, Inc.
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 Qiagen N.V.
8.3.8.1 Company Overview
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 Spectral Diagnostics
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 Instrumentation Laboratory
8.3.10.1 Company Overview
8.3.10.2 Financial Performance
8.3.10.3 Product Benchmarking
8.3.10.4 Strategic Initiatives
8.3.11 Johnson and Johnson
8.3.11.1 Company Overview
8.3.11.2 Financial Performance
8.3.11.3 Product Benchmarking
8.3.11.4 Strategic Initiatives
8.3.12 Nova Biomedical
8.3.12.1 Company Overview
8.3.12.2 Financial Performance
8.3.12.3 Product Benchmarking
8.3.12.4 Strategic Initiatives
8.3.13 Nipro Diagnostics Inc
8.3.13.1 Company Overview
8.3.13.2 Financial Performance
8.3.13.3 Product Benchmarking
8.3.13.4 Strategic Initiatives
8.3.14 HemoCue AB
8.3.14.1 Company Overview
8.3.14.2 Financial Performance
8.3.14.3 Product Benchmarking
8.3.14.4 Strategic Initiatives
8.3.15 International Technidyne Corporation (ITC)
8.3.15.1 Company Overview
8.3.15.2 Financial Performance
8.3.15.3 Product Benchmarking
8.3.15.4 Strategic Initiatives
8.3.16 Quidel Corporation
8.3.16.1 Company Overview
8.3.16.2 Financial Performance
8.3.16.3 Product Benchmarking
8.3.16.4 Strategic Initiatives
8.3.17 Trinity Biotech PLC
8.3.17.1 Company Overview
8.3.17.2 Financial Performance
8.3.17.3 Product Benchmarking
8.3.17.4 Strategic Initiatives
8.3.18 Sekisui Diagnostics LLC
8.3.18.1 Company Overview
8.3.18.2 Financial Performance
8.3.18.3 Product Benchmarking
8.3.18.4 Strategic Initiatives
8.3.19 OraSure Technologies Inc
8.3.19.1 Company Overview
8.3.19.2 Financial Performance
8.3.19.3 Product Benchmarking
8.3.19.4 Strategic Initiatives
LIST OF TABLES
Table 1 Country share estimation
Table 2 Market driver relevance analysis (Current & future impact)
Table 3 Market restraint relevance analysis (Current & future impact)
Table 4 North America point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 5 North America point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 6 North America point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 7 North America point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 8 North America point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 9 North America point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 10 U.S. point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 11 U.S. point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 12 U.S. point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 13 U.S. point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 14 U.S. point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 15 U.S. point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 16 Canada point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 17 Canada point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 18 Canada point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 19 Canada point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 20 Canada point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 21 Canada point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 1 Country share estimation
Table 2 Market driver relevance analysis (Current & future impact)
Table 3 Market restraint relevance analysis (Current & future impact)
Table 4 North America point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 5 North America point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 6 North America point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 7 North America point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 8 North America point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 9 North America point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 10 U.S. point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 11 U.S. point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 12 U.S. point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 13 U.S. point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 14 U.S. point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 15 U.S. point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
Table 16 Canada point of care diagnostics market estimates, by product, 2013 - 2015 (USD Million)
Table 17 Canada point of care diagnostics market forecasts, by product, 2016 - 2024 (USD Million)
Table 18 Canada point of care infectious diseases diagnostics market estimates, by disease, 2013 - 2015 (USD Million)
Table 19 Canada point of care infectious diseases diagnostics market forecasts, by disease, 2016 - 2024 (USD Million)
Table 20 Canada point of care diagnostics market estimates, by end-use, 2013 - 2015 (USD Million)
Table 21 Canada point of care diagnostics market forecasts, by end-use, 2016 - 2024 (USD Million)
